Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00028067
Status:
TERMINATED
Last Update Posted:
2011-05-04
First Post:
2001-12-10
Brief Title:
A Comparison of Atazanavir and Nelfinavir Each in Combination With 2 NRTIs in Patients Who Have Failed Treatments Without a Protease Inhibitor
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase III Study Comparing the Antiviral Efficacy and Safety of Atazanavir With Nelfinavir Each in Combination With Dual Nucleoside Therapy in HIV-Infected Subjects Who Have Failed a Regimen Not Containing a Protease Inhibitor
Status:
TERMINATED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the atazanavir and nelfinavir NFV treatments in their ability to reduce viral load
Detailed Description:
In this double-blind double-placebo randomized 2-arm study atazanavir and NFV each are given in combination with 2 open-label nucleoside reverse transcriptase inhibitors NRTIs over 48 weeks Patients assigned to atazanavir will receive placebo capsules which are identical in size and appearance to NFV Patients assigned to NFV will receive placebo capsules which are identical in size and appearance to atazanavir HIV levels are monitored
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI424-037 | None | None | None |